1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Lilly Has Early Access Rights To BioAge’s ‘Exercise In A Pill’ Data

 
• By Andrew McConaghie

The big pharma will get a first peak at BioAge’s Phase II results for azelaprag, but the biotech is keeping its options open with an ‘incretin-agnostic’ strategy for its exerkine candidate.

(Shutterstock)

In the huge rush of investment into the obesity therapy field, companies are looking for drugs with a truly novel mechanism to go beyond the existing GLP-1 agonist-based blockbusters.

BioAge, with its oral small molecule, azelaprag, is a frontrunner in the novel field of apelin receptor agonists. Known as an “exercise exerkine”, apelin is...

Key Takeaways
  • BioAge recently went public with a $189m IPO, and its lead asset azelaprag is on course for a Phase II readout in Q3 2025.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Angelini Advances Brain Health Ambitions With GRIN Pact

 
• By Kevin Grogan

The Italian drugmaker gets rights to Phase III-ready asset radiprodil.

Sweden’s Hansa Slims Down Ahead of Key Readouts

 
• By Kevin Grogan

New CEO Renée Aguiar-Lucander is marking her mark.

Gilead Ready To Go After Hepatitis D Again

 
• By Joseph Haas

Following an FDA complete response in 2022, Gilead is getting ready to refile bulevirtide for hepatitis D. The drug already is approved in the EU, UK and elsewhere.

Progress In The Effort To Improve Outcomes In SCLC

 
• By Jessica Merrill

Several drug makers are working to bring new advances to small-cell lung cancer, a fast-growing cancer with limited treatment options.

More from Scrip

GlycoEra’s Series B Cash Will Fund Efforts To Take On FcRn Inhibitor Class

 
• By Joseph Haas

GlycoEra unveiled a $130m series B financing, saying the proceeds would enable it to take its first clinical candidate through proof-of-concept in autoimmune diseases.

Sweden’s Hansa Slims Down Ahead of Key Readouts

 
• By Kevin Grogan

New CEO Renée Aguiar-Lucander is marking her mark.

Ascentage Broadens Horizons As Pipeline Shows Renewed Promise

 
• By Xu Hu

Ascentage will share at ASCO new clinical data on its Bcl-2 inhibitor lisaftoclax, part of the Chinese firm's novel pipeline, on which its CEO shared with Scrip plans and strategy, along with some views on the use of RWD in China.